MoH and SFDA registration across the GCC — dossier prep, legalisation, submission support.
CTD dossiers for Saudi Arabia, the UAE, Kuwait, Oman, Qatar and Bahrain — prepared at the Indian manufacturer's end, cross-referenced to the site master file, and handed to your local marketing authorisation holder ready to file. Legalisation chain, artwork, pricing dossier and variations included.
We prepare the dossier once. Your local MAH submits it six times.
SFDA — Saudi Arabia
SFDA-eCTD submission, pricing file referenced to 30 countries, CoPP legalisation through the Saudi embassy in New Delhi, site inspection liaison. Generic registration window, recent experience: 12-18 months.
MoHAP / EDE — UAE
Federal registration via MoHAP and the Emirates Drug Establishment, plus emirate-level health authority notifications (DHA Dubai, DoH Abu Dhabi). Arabic / English artwork, Gulf reference pricing. Window: 8-14 months for generics.
Kuwait MoH
Drug and Food Control Department, central tender-focused. Registration often tied to the next tender cycle. Window: 10-16 months.
MoH Oman
Directorate General of Pharmaceutical Affairs and Drug Control. Gulf pricing applies; CoPP and GMP legalisation required. Window: 10-16 months.
MoPH Qatar
Pharmacy and Drug Control Department. Hamad Medical Corporation remains the anchor buyer. Window: 12-18 months.
NHRA — Bahrain
National Health Regulatory Authority. Often the fastest GCC registration path and a useful anchor for onward GCC-DR submissions. Window: 8-12 months.
CTD Module 1 to 3, prepared to the regulator's format — not ours.
GCC regulators have converged on the ICH CTD structure but each asks for destination-specific content in Module 1. We prepare what SFDA wants for SFDA and what MoPH wants for MoPH, rather than a generic file with a cover page swap.
Module 3 — CMC
Full drug substance and drug product dossier. Manufacturing process, in-process controls, analytical methods with validation reports, specifications, stability (long-term and accelerated, ICH zone IVa for GCC), container closure, batch analysis.
Module 2 — summaries
Quality overall summary, non-clinical and clinical overviews and summaries. Cross-references to Module 3 and, for known molecules, to published literature where permitted.
Module 1 — country-specific
Cover letter, application form in regulator template, proposed SmPC / PIL / labelling in Arabic and English, product information leaflet QC'd against MoH style guide, pricing file with reference prices.
Legalisation chain
CoPP, WHO-GMP, manufacturing licence, Free Sale Certificate — each notarised in India, MEA-attested, then embassy-attested at the destination country's mission in New Delhi. Apostille is not accepted by GCC regulators; the full chain is.
Artwork & labelling
Primary and secondary pack artwork in Arabic and English to MoH style. Braille on secondary where required. Pantones and cutter guide to the manufacturer's print supplier. QC round on artwork proofs before the regulator sees them.
Pricing dossier
Reference-country pricing table (often 30 comparator countries), ex-factory vs public-price breakdown, internal-reference-pricing methodology explanation. Critical at SFDA and MoHAP; often decides the registration commercial viability.
Registration is the start of the file, not the end.
The dossier we build is a live file. Variations, renewals, PSURs and the next tender all pull from it.
Variations
Type IA, IB and II variations filed to keep the dossier current. Change of manufacturing site, API source, specification tightening, pack-size addition — each tracked against the original submission.
Renewals
Five-year renewals for SFDA, MoHAP, Kuwait, Oman, Qatar and Bahrain. Renewal package assembled 12 months ahead of expiry — missing a GCC renewal window is expensive.
PSURs
Periodic Safety Update Reports to ICH E2C, submitted on the regulator's cadence. Adverse drug reaction reporting through the nominated local PV contact.
Tender packs
Each tender cycle pulls a subset of the dossier into a tender-specific pack. NUPCO, MoH Kuwait, DoH Abu Dhabi, DHA Dubai, Hamad Medical — each with its own technical specification template. Prepared against the live file.
Molecule · target country · local MAH · target first shipment. Inside one working day.
- Send the specifics. INN, dosage form, strengths, target GCC country or countries, name of your local marketing authorisation holder if appointed, and whether you are building for tender, hospital, or retail channel.
- Dossier scoping. Module 3 gap analysis against the nominated Indian manufacturer's existing file, legalisation chain status, artwork scope, pricing file requirement. Costed offer against each country.
- Drafting and QC. Module 1-3 drafted, internally QC'd against the regulator's latest published guideline, artwork prepared, legalisation triggered on the Indian side.
- Hand-over to local MAH. Pack shared electronically and physically for the local marketing authorisation holder to submit. We stay in the loop for queries, deficiencies and site inspection.
- Post-approval support. Variations, renewals, PSURs and tender packs all pulled from the live file. One manufacturer-side contact for the life of the registration.
GCC MoH registration — the specifics.
Can M Care act as the marketing authorisation holder in the GCC?
No. GCC marketing authorisations require an in-country entity with a local pharmaceutical licence — an importer, distributor or hospital supply company. We prepare the manufacturer-side dossier and hand to your nominated MAH.
Does the central GCC-DR registration still exist?
Yes — the centralised Gulf Health Council drug registration runs in parallel to national registrations. It takes longer (18-24 months) but unlocks all six states from one approval. Many sponsors file GCC-DR and NHRA Bahrain in parallel to secure an early in-market anchor.
What does the legalisation chain look like?
Notarisation in India → MEA attestation → destination-country embassy attestation in New Delhi. CoPP, WHO-GMP, manufacturing licence and Free Sale each go through this chain. Apostille alone is not accepted by GCC regulators.
How long does SFDA registration take right now?
In our recent experience, 12-18 months from clean submission to marketing authorisation for a generic molecule, subject to response windows on queries. SFDA publishes quarterly queue updates; our quote will reference the current state rather than textbook figures.
What is the pricing dossier, and which regulators require it?
A reference-country pricing table (typically 30 comparator countries), ex-factory vs public-price breakdown, and the internal-reference methodology. Required at SFDA and MoHAP explicitly, commonly requested by other GCC regulators. It often decides the commercial viability of the registration.
Do you handle artwork in Arabic?
Yes — primary and secondary pack artwork in Arabic and English to the destination regulator's style guide. Braille on secondary packs where required (SFDA and increasingly MoHAP). QC round on proofs before the regulator or the printer sees them.
What is the difference between a tender dossier and a full registration?
A tender dossier is a simpler pack: technical specification, CoA sample, CoPP, manufacturer declaration, price. It supports tender participation without securing a full marketing authorisation. Many GCC tenders (MoH Kuwait, NUPCO, DoH, DHA, Hamad Medical) run on tender dossiers; full registration is the commercial foundation that sits under them.
Can you track tender cycles?
Yes. We maintain a GCC tender calendar across the main central and institutional buyers — publication date, submission window, award window, supply window. We flag cycles that match your portfolio against your registration status.
One dossier, six regulators. Start with a molecule and a country.
INN, dosage form, strengths, target GCC country, local MAH status, channel. A costed manufacturer-side offer inside one working day.